AZNAstraZenecaRunning, no new patients
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
Non-small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 51 (final count)
- Started
- Feb 9, 2023
- Main results expected
- Jun 30, 2029
- Fully finished
- Jun 30, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
3-year disease-free survival (DFS) rate by investigator assessment
Measured over: Up to 3 years for each subject from the first dosing of study treatment.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05546866 · record last updated 2026-08-06 · checked 2026-11-09 15:47 UTC